DENVER, May 3, 2012 /PRNewswire/ -- MusclePharm Corporation (OTCBB: MSLP), a nutritional supplement company focusing on all categories of an active lifestyle, today said that, in light of yesterday's FDA ban on the substance DMAA, which is not used in MusclePharm products, it expects to capture a wider market share, particularly for the company's pre-workout supplement Assault™, which is the only pre-workout product on the market that is certified by both NSF International and Informed Choice as free of banned substances. Yesterday, the United States Food and Drug Administration (FDA) imposed a ban on the supplement 1,3-Dimethylamine (DMAA), an ingredient used by many supplement companies MusclePharm competes with, citing its potentially fatal side effects.
"MusclePharm is committed to providing products that are safe, effective and free of any banned substances," said Dr. Roscoe Moore, former U.S. Assistant Surgeon General and Chief Scientific Director for MusclePharm. "We have a top-notch team of physicians and other medical experts, we well as a highly competent Scientific Advisory Board, that oversee the creation and production of all of our products. MusclePharm made an intentional decision to stay away from DMMA when it formulated the pre-workout product, Assault, for the same reasons the FDA has now banned the ingredient. We believe this differentiates MusclePharm from its competitors and ensures our products are backed by real science."
The company's product, Assault, has become the No. 1-selling pre-workout supplement on Bodybuilding.com, the world's largest online nutritional retailer. Assault contains large amounts of Branch-Chain Amino Acids (BCAAs) and Beta Alanine and Creatine, which have been proven to naturally increase performance in athletes.
"Developed at the state-of-the-art MusclePharm Sports Science Center, Assault is one of the most researched and rigorously tested pre-workout supplements on the market," said MusclePharm Chief Executive Officer Brad Pyatt. "By offering high quality, scientifically backed products, MusclePharm is a leading supplement company that is able to back up its claims with a wide array of clinical studies and scientific research. We believe this is why so many athletes, professional baseball organizations and the UFC partner with us, and why we believe MusclePharm is the future in the sports nutrition industry."
A recently-released peer-reviewed journal, Nutrition and Metabolism, published a scientific paper showing positive results on the Phase 1 clinical trial of the company's pre-workout supplement, Assault. Conducted at the United States Sports Academy (USSA) (www.ussa.edu), the study suggests that ingesting Assault 20 minutes prior to exercise can improve agility, quickness and lower-body muscular strength in both strength and/or endurance-trained young adult males. Moreover, the study showed that Assault can improve energy, focus and alertness, and delay fatigue.
"Our findings suggest that Assault can provide athletes with an overall better workout experience by prolonging exercise performance, reducing fatigue and increasing energy-levels," said Jordan R. Moon, Ph.D., lead researcher of the clinical trial and USSA's Head of the Department of Sports Fitness and Health. "The athlete-subjects who consumed Assault lifted more weight, were faster in reaction tests and were motivated to continue to exercise."
The abstract is entitled "Ingesting a pre-workout supplement containing caffeine, B-vitamins, amino acids, creatine, and beta-alanine before exercise delays fatigue while improving reaction time and muscular endurance" and can be downloaded at www.nutritionandmetabolism.com/content/9/1/28/abstract.
ABOUT MUSCLEPHARM CORPORATION
MusclePharm is a healthy life-style company that develops and manufactures a full line of NSF International and Informed Choice approved nutritional supplements that are free of banned substances. Based on years of research at the MusclePharm Sports Science Center, the products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than one hundred elite professional athletes from various professional sports leagues including the National Football League, Mixed Martial Arts and Major League Baseball. The company's products address all categories of an active lifestyle, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in more than 120 countries and available in over 10,000 U.S. retail outlets, including Dick's Sporting Goods, GNC, Vitamin Shoppe, Vitamin World and Walmart. MusclePharm products also are sold through more than 100 online stores, including bodybuilding.com, Amazon.com and Vitacost.com. For more information, please visit www.musclepharm.com.
FORWARD LOOKING STATEMENTS
The information contained herein includes forward-looking statements. These statements, including, but not limited to, capturing a wider market share for its products based on the ban of the substance DMAA, relate to future events or to future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Undue reliance should not be placed on forward-looking statements, since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. MusclePharm assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information, contact:
Roger Pondel/Robert Jaffe
SOURCE MusclePharm Corporation